Clinical trials: Myelodysplasia
Leukemia, Myelodysplastic Syndromes
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome
RATIONALE: Giving low doses of chemotherapy and antithymocyte globulin before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Trial name
- NCT00732316
- Testing
- nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Asan Medical Center
Myelodysplastic Syndromes
Follow-up Study of ICUS and CCUS Patients
The proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions has been released by an international consensus group.
- Trial name
- NCT04428489
- Testing
- Observation and necessary supportive care
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
Allo-HSCT is the most effective way to cure high-risk MDS patients. At present, the best conditioning regimen for high-risk MDS patients undergoing allo-HSCT remains in discussion.
- Conditions
- Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT05453552
- Testing
- Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Myelodysplastic Syndrome
Spanish Registry of Erythropoietic Stimulating Agents Study
Reviewing Spanish record of myelodysplastic syndromes (RESMD) data base in the group of patients with MDS. The information will be collected retrospectively from diagnosis of MDS, until the date of December 31, 2011.
- Trial name
- SPRESAS (NCT01739452)
- Volunteers
- 722 people
- Sponsor
- Grupo Español de Síndromes Mielodisplásicos
Myelodysplastic Syndrome
Erlotinib Study for Myelodysplastic Syndrome (MDS)
The purpose of this research study is to find out what effects, good and/or bad, erlotinib has on the patient and their myelodysplastic syndrome.
- Trial name
- NCT00977548
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Trial name
- NCT06059391
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor
- Where
- 3 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Paroxysmal Nocturnal Hemoglobinuria
A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of ravulizumab in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH).
- Trial name
- NCT03406507
- Testing
- Ravulizumab
- Where
- 9 sites in United States, France and 4 more
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Myelodysplastic Syndrome
Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome
To evaluate the overall response rate of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients (INT-2 and High risk defined by IPSS), and patients with low and int-1 who are considered to be at high risk due…
- Trial name
- ViLen 001 (NCT01053806)
- Testing
- 5-Azacytidine and Lenalidomide
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Paroxysmal Nocturnal Hemoglobinuria
Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
This study will collect clinical response data on participants who were already treated with eculizumab for at least 26 weeks and who started ravulizumab treatment as a specific therapeutic strategy as per ordinary clinical…
- Trial name
- NCT05274633
- Testing
- Ravulizumab
- Where
- 6 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
This study is designed to evaluate the combination of LBH589 and decitabine in patients age ≥ 60 years with high risk Myelodysplastic Syndrome (IPSS Int-2 or High) or Acute Myeloid Leukemia.
- Trial name
- NCT00691938
- Testing
- LBH589, Decitabine
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- AML-MDS 001 (NCT07270978)
- Testing
- CD33 FPBMC
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Virginia
Leukemia, Lymphoma
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care…
- Conditions
- Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT05745285
- Testing
- LLS Program
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Miami
Leukemia, Myeloid, Myelodysplastic Syndromes
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
The goal of this clinical research study is to learn if clofarabine, when given in combination with ara-C (cytarabine), can help to improve the disease's response to therapy and to increase the duration of response in patients…
- Trial name
- NCT00065143
- Testing
- clofarabine, Ara-C
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS
Indication:Relapsed or refractory AML in patients for whom no established treatment options are available (this indication will heretofore be referred to as the protocol AML indication), or adult patients with MDS who are…
- Trial name
- NCT04743115
- Testing
- BS HH 002.SA
- Volunteers
- 66 people
- Sponsor
- Shanghai Bensen Pharmaceutical Co., Ltd.
Acute Leukemia, Myelodysplasia
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.
- Conditions
- Acute Leukemia, Myelodysplasia, Chronic Graft-versus-host-disease
- Trial name
- NCT04202835
- Testing
- Cyclophosphamide, Anti-Thymocyte globulin (rabbit)
- Where
- 9 sites in Australia, Canada
- Volunteers
- 80 people
- Sponsor
- McMaster University
Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).
- Trial name
- NCT05365035
- Testing
- Cladribine, Cytarabine, Venetoclax
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005092
- Testing
- Cyclophosphamide, Psoralen, Thiotepa
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogeneic signal is present.
- Trial name
- NCT00413114
- Testing
- Obatoclax mesylate (GX15-070MS)
- Where
- 22 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Gemin X
Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential
CHIP in Health and Disease
Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), is an age-associated condition characterized by the expansion of hematopoietic stem and progenitor cell clones carrying acquired somatic…
- Conditions
- Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential, Clonal Cytopenia of Undetermined Significance (CCUS), Myelodysplastic Syndrome
- Trial name
- CHIP2 (NCT07780552)
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- VASCage GmbH
Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS)
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
Background: Severe aplastic anemia (SAA), and myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) cause serious blood problems.
- Conditions
- Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Trial name
- NCT03520647
- Testing
- Cyclophosphamide, Peripheral Blood Stem Cells
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.